Phase I results for bortezomib in children with refractory solid tumors
This article has no abstract so we have provided the first paragraph of the full text.
Bortezomib, a proteasome inhibitor, has shown activity against a variety of tumor types in preclinical studies and has been licensed as a third-line treatment for adults with multiple myeloma. Blaney et al. have recently reported the results of their phase I study of bortezomib in children with recurrent or refractory solid tumors.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Smallpox, polio and now a cancer vaccine?Nature Medicine News and Views (01 Mar 2000)
Vessel maneuvers: Vaccine targets tumor vasculatureNature Medicine News and Views (01 Dec 2002)